Big News! Our VP of R&D, Dr. Elana Gazal, is set to speak at the Winter School of Biofabrication in Rastatt, Austria. She'll delve into taking products from bench to market and discuss our pioneering 3D Bioprinted Regenerative Breast Implants.
https://t.co/MHIOkdINnQ
📣 Exciting news! #CollPlant CEO Yehiel Tal will speak at Octane's Aesthetic Tech Forum (Jan 25-26, Balboa Bay Resort, CA). He'll discuss our innovative 3D Bioprinted Regenerative Breast Implants made with our rhCollagen.#MedicalAesthetics!
👉 https://t.co/QM8WqqYfJK
📢 Exciting news! 🌟CollPlant has been granted a patent by the U.S. Patent Office for our groundbreaking dermal filler product candidate in aesthetics. Advancing regenerative medicine with innovation!
Read the full PR- https://t.co/vuqiyLG9i1
#CollPlant#Aesthetics#Patent
CollPlant warmly congratulates @Donald E. Ingber, M.D., Ph.D. the Founding Director of the Wyss Institute for Biologically Inspired Engineering at Harvard University for winning the Russell and Burch award to scientists who have made outstanding contributions to the advancement
of alternative methods in the areas of research, testing or higher education. Dr. Ingber is one of the pioneers behind the development of organ-on-a-chip technology, which is now being used to help replace animal testing for drug development and personalized medicine.
The annual international conference on Biofabrication is just around the corner! If you are attending, join us for the keynote presentation by our VP R&D Elana GazalVisit our booth #1. Stop by to chat and hear the latest about our rhCollagen and Collink.3D products line.
At CollPlant, we are firmly committed to our Environmental, Social, and Governance (ESG) responsibilities. As a part of this commitment, we have carefully selected and aligned ourselves with the relevant Sustainable Development Goals (SDGs) outlined by the United Nations.
These SDGs serve as a guiding framework for our efforts to create a positive and lasting impact on our planet and society as a whole. Stay tuned as we will elaborate in the upcoming weeks on those SDG’s which lie at the core of CollPlant’s business.
#sustainability#ESG
"The collaboration with #AbbVie allows us to co-develop what could be the first aesthetic product utilizing our #rhCollagen, with a worldwide #leader in biopharmaceutical health.”
read more about this exciting achievement:
https://t.co/kV2Fqtk7Bt
#collaboration#medicalaesthetics
We are proud to announce a milestone achievement in the Regenerative Dermal Filler Product collaboration with AbbVie. Yehiel Tal, CEO, stated: “We are very pleased with the significant progress made with the dermal filler program and the achievement of this milestone.
With more than 300 scientific publications and over 94 patents, our founder and Chief scientist, Prof. Oded Shoseyov, was nominated as one of “48 Israelis, who are uniquely shaping Israel and the world” on ISAREL21c Magazine addition celebrating Israel’s 75th Independence Day
We’re Hiring!
We are looking for talented, motivated people to join our company.
Have a look at our open positions here:
https://t.co/0CUyxRkte3
#CollPlant#career#3dbioprinting
"We remain highly focused on becoming a global leader in regenerative medicine with our pioneering collagen-based platform to help people live longer and better”-Yehiel Tal, CEO.
For 2022 full-year financial results and corporate updates: https://t.co/yV8rEaV78q
Come and meet the team!
We will be exhibiting at the upcoming Termis-EU, Manchester 2023.
You are invited to stop by booth 14, and discover more about CollPlant and our Bioinks line.
See you there!
#CollPlant#regenerativemedicine#tissueengineering